HUTCHMED (China) Limited provided revenue guidance for the year 2022. For the year, the company expects Oncology/Immunology consolidated revenues of $160 million $190 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
296 GBX | -2.63% | -8.64% | +4.59% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.59% | 3.3B | |
+38.51% | 728B | |
+33.05% | 603B | |
-6.23% | 360B | |
+18.78% | 332B | |
+1.35% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.19% | 164B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED Limited Provides Revenue Guidance for the Year 2022